RxDoctor Payments DataLook up a doctor →

Matthew Nichols, MD

Gastroenterology · Lone Tree, CONPI 1952451379

Payments from drug & device makers

$395,783in general payments, 2019–2025

Across 937 payments — averaging $422.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247K
  • Lilly USA, LLC$63K
  • Johnson & Johnson$39K
  • Janssen Research & Development, LLC$21K
  • Gilead$16K
  • Eli Lilly$5K
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$20,0006%
  • Speaking & faculty fees$293,50982%
  • Travel & lodging$28,4358%
  • Food & beverage$17,5205%
  • Education$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$395,783 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$363,084
Medicare patients
279
Services billed
13,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab37$1,076,775
RinvoqUpadacitinib50$334,094
CreonLipase/Protease/Amylase26$72,067
LinzessLinaclotide17$20,386
SutabSod Sulf/Pot Chloride/Mag Sulf101$16,521
Mesalamine31$16,269
MotegrityPrucalopride Succinate15$12,734
Budesonide DrBudesonide57$10,416
Dexlansoprazole DrDexlansoprazole27$9,477
Mercaptopurine18$3,282
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine60$2,437
Azathioprine15$2,285
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag17$2,156
Pantoprazole Sodium149$1,792
Omeprazole67$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$38,991$1,076,77537 claims
AbbVieRinvoq, Creon, Linzess$247,445$426,54793 claims
Braintree Laboratories, Inc.Sutab, Suflave$68$18,678118 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,129$12,73415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →